Recent Updates
Recently added Catalysts
SRPT Negative Sentiment

SAREPTA THERAPEUTICS, INC. (NASDAQ: SRPT) SHAREHOLDER ALERT Bernstein Liebhard LLP Reminds Sarepta Therapeutics, Inc. Investors of Upcoming Deadline

Key Takeaway: Sarepta Therapeutics, Inc. is currently involved in a securities fraud class action lawsuit that alleges misrepresentations regarding the safety of its treatment for Duchenne muscular dystrophy, ELEVIDYS. The lawsuit, filed in the Southern District of New York, targets the company and its senior officers, claiming violations of the Securities Exchange Act of 1934. Shareholders are reminded of an impending deadline to file as lead plaintiffs in this case. Investors may face financial repercussions stemming from the allegations made in the lawsuit.
Price reaction · baseline $15.91 (2025-08-01 close) · 4 other SRPT headline(s) in the window, move may be shared
day 0 close
+7.5%
day 1
+5.3%
day 3 · peak
+12.9%

Market Sentiment Analysis

CONCERNS & RISKS

  • Sarepta is facing a securities fraud class action lawsuit due to misrepresentations about the safety risks of its product, ELEVIDYS.
  • The lawsuit alleges violations of the Securities Exchange Act of 1934, which could lead to significant legal challenges for the company.
  • Investors who purchased shares during the specified period may have lost money, indicating potential financial damage.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+46%
120-day peak, hindsight
Typical move
16.8%
average across 4 past catalysts
Lead asset
Eteplirsen
Phase 3 · Muscular Dystrophy, Duchenne

Full Press Release Details

NEW YORK, Aug. 04, 2025 (GLOBE NEWSWIRE) -- Bernstein Liebhard LLP, a nationally acclaimed investor rights law firm, reminds Sarepta Therapeutics, Inc. (“Sarepta” or the “Company”) (NASDAQ: SRPT) investors of an upcoming deadline involving a securities fraud class action lawsuit commenced against the Company.
Should You Join This Class Action Lawsuit?
Do you, or did you, own shares of Sarepta Therapeutics, Inc. (NASDAQ: SRPT)?
Did you purchase your shares between June 22, 2023 and June 24, 2025, inclusive?
Did you lose money in your investment in Sarepta Therapeutics, Inc.?
If you purchased or acquired Sarepta securities, and/or would like to discuss your legal rights and options please visit Sarepta Therapeutics, Inc. Shareholder Class Action Lawsuit or contact Investor Relations Manager Peter Allocco at (212) 951-2030 or pallocco@bernlieb.com.
A lawsuit was filed in the United States District Court for the Southern District of New York on behalf of investors who purchased or acquired the securities of Sarepta between June 22, 2023 and June 24, 2025, inclusive, alleging violations of the Securities Exchange Act of 1934 against the Company and certain of its senior officers.
According to the lawsuit, defendants made misrepresentations concerning the safety risks to patients posed by ELEVIDYS, the Company’s product designed to treat Duchenne muscular dystrophy.
If you wish to serve as lead plaintiff for the Class, you must file papers by August 25, 2025. A lead plaintiff is a representative party acting on other class members’ behalf in directing the litigation. Your ability to share in any recovery doesn’t require that you serve as lead plaintiff. If you choose to take no action, you may remain an absent class member.
All representation is on a contingency fee basis. Shareholders pay no fees or expenses.
Since 1993, Bernstein Liebhard LLP has recovered over $3.5 billion for its clients. In addition to representing individual investors, the Firm has been retained by some of the largest public and private pension funds in the country to monitor their assets and pursue litigation on their behalf. As a result of its success litigating hundreds of class actions, the Firm has been named to The National Law Journal’s “Plaintiffs’ Hot List” thirteen times and listed in The Legal 500 for sixteen consecutive years.
ATTORNEY ADVERTISING. © 2025 Bernstein Liebhard LLP. The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, (212) 779-1414. Prior results do not guarantee or predict a similar outcome with respect to any future matter.
Contact Information:
Investor Relations Manager
Bernstein Liebhard LLP

Frequently Asked Questions

What is the deadline for Sarepta class action lawsuit?

The deadline to file papers to serve as lead plaintiff is August 25, 2025.

Who can join the Sarepta class action lawsuit?

Investors who purchased Sarepta shares between June 22, 2023, and June 24, 2025, can join.

What is the basis of the Sarepta lawsuit?

The lawsuit alleges misrepresentations about safety risks associated with ELEVIDYS.

Do I need to pay fees to join the class action?

No, all representation is on a contingency fee basis, meaning no upfront costs.

How can I contact for more information about the lawsuit?

You can contact Investor Relations Manager Peter Allocco at pallocco@bernlieb.com.

Last updated: Aug 4, 2025